Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Effective antiemetic therapy is crucial for patient tolerance of chemotherapy.
• Understanding both antiemetic drugs and chemotherapy's emetogenic potential is key.
• Current methods for classifying chemotherapy emetogenicity need refinement.

Purpose of the Study:

• To outline a structured approach for developing and evaluating new antiemetic agents.
• To emphasize the importance of rigorous clinical trial phases for antiemetics.
• To propose a classification system for the emetogenicity of antineoplastic agents.

Main Methods:

• Phase I, II, and III clinical trials for new antiemetic agents.
• Randomized double-blind trials comparing new agents to standard therapy.
• Development of a four-level classification system for intravenous and oral antineoplastic agent emetogenicity.

Main Results:

• Placebo use is deemed unacceptable in trials against highly or moderately emetogenic chemotherapy.
• Separate evaluation of acute and delayed nausea and vomiting is recommended.
• Proposed classification systems for both intravenous and oral antineoplastic agent emetogenicity.

Conclusions:

• A systematic approach to antiemetic drug development and evaluation is necessary.
• Standardized classification of antineoplastic agent emetogenicity will aid in therapy selection.
• Rigorous trial design and appropriate patient monitoring are essential for advancing antiemetic care.